"IMO, DECN needs a Board of Directors that has more than 2
"IMO, DECN needs a Board of Directors that has more than 2 people of which one is Berman, the DECN CEO. The current BOD lacks numbers as well as the necessary skillset in marketing, sales, ecommerce, PR, etc. and execution. IMO, the shareholders interests are not being protected by the current BOD - Berman and his crony."
From the iHub message board written by AC143 / billdecn. A couple of things:
1. Messrs. Berman and Jagunich together have 85 years of experience in the in-vitro diagnostics industry.
2. Both of these men have skills sets different than AC143 / billdecn who's only claim to a skill set is that he was a U.S. Marine. P.S. so am I, but I went out and laid claim to a real skill set.
Message to billdecn / AC143. Call the cops. Call the SEC. Call the Delta Force. Call the FBI. Have at it butthole.
It appears that the continued stock ownership by billdecn / AC143 is regime change. Bring it on. Nothing would please me more than to see the company turned over to a U.S. Marine without a skill set.
3
Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Hyzon Motors Announces Delisting from Nasdaq Hyzon Motors Inc. is making a significant shift regarding its stock trading status. This U.S. company, known for its commitment to high-performance hydrogen fuel cell technology, has decided to inform Nasdaq Stock Market of its intent to delist its Class A common stock and publicly traded warrants. This move comes as part of...
Continue Reading
Your Gateway to High Returns in Crypto Staking As the digital currency landscape continues to expand, platforms like Keynode.net are leading the charge in offering unprecedented opportunities for investors. For those seeking impressive annual percentage yields (APY) through crypto staking, Keynode.net has emerged as a premier choice. Its user-friendly interface, robust...
Continue Reading
Overview of the Class Action Lawsuit Against Rocket Pharmaceuticals Pomerantz LLP has initiated a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) highlighting various concerns regarding the company's business practices. Investors who have suffered losses during the stipulated Class Period should take note of this unfolding situation. Key Details...
Continue Reading
Revitalizing Economic Growth at the 23rd SMDO Conference The 23rd Annual South Metro Development Outlook (SMDO25) Conference stands as a pivotal forum for industry leaders, policymakers, and community stakeholders. It is designed to foster collaboration and tackle some of the most pressing issues faced by the region today. Set against the backdrop of changing federal...
Continue Reading
Strong First Quarter Results for SciBase In the recent interim report, SciBase has showcased an impressive performance for the first quarter of 2025. The medical technology company, renowned for its innovative dermatological solutions, recorded net sales of TSEK 8,856, marking a remarkable increase of 46% from the previous year’s figures. Financial Performance Overview...
Continue Reading